SIRT2 and urinary bladder cancer: Tubacin administration at micro-molar concentrations, combined with the siRNA-mediated knockout of SIRT2, caused the suppression of cell migration and invasion, thus indicating tubacin as a promising therapeutic agent for bladder cancer therapy [178].